Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of ...

The funding round, led by Novartis and OrbiMed, will allow Sidewinder to progress two of its bispecific ADC programmes to ...

Three years after its OrbiMed-backed series A in 2023, Sidewinder Therapeutics is adding to its nest egg courtesy of a clutch ...

Recurrent/metastatic EC has a poor long-term prognosis, and treatment options are limited beyond first line, said Pothuri.

Abdullah also attributed GSK’s willingness to go all-in on mo-rez on the leadership of Luke Miels, who stepped up as CEO of ...

Gilead’s third acquisition since late February hands it a technology designed to make antibody-drug conjugates less toxic and ...

The FDA has granted Fast Track designation to the investigational antibody-drug conjugate (ADC) SIM0505 for the treatment of women with platinum-resistant ovarian cancer. The designation adds SIM0505 ...

Real-world data show ADCs benefit more diverse, older and pretreated patients, helping guide care and build confidence beyond ...

Backed by OrbiMed, Novartis’ venture arm and many other investors, the biotech is among those working on newer technology ...

The FDA has granted Fast Track designation to ZW191, an antibody-drug conjugate (ADC) targeting folate receptor-α (FRα), for ...